Early in her career, Glinski spent time in
neuropsychopharmacology research supporting discovery of novel treatments for schizophrenia and depression.
The FDA granted Breakthrough Therapy Designation for SEP-363856 based on pivotal, Phase 2 data from Study SEP361-201, which were presented by Sunovion at the 57th annual meeting of the American College of
Neuropsychopharmacology in December 2018, as well as data from Study SEP361-202, a six-month, open-label, safety and tolerability extension study.
The results were published in European
Neuropsychopharmacology.
The findings were published in the Journal
Neuropsychopharmacology.
BARCELONA -- Four potent clinical predictors of treatment-resistant depression have been confirmed in a validation study that showed the four factors collectively have a predictive accuracy of 87%, Alexander Kautzky, MD, reported at the annual congress of the European College of
Neuropsychopharmacology.
Trevena announced that TRV734 data were featured in a presentation at the annual meeting of the American College of
Neuropsychopharmacology as part of Trevena's ongoing collaboration with the National Institute on Drug Abuse, or NIDA.
The study, published in the journal
Neuropsychopharmacology Reports, explored a small group of young and healthy volunteers with normal work hours and sleep habits to find out if the "hypothalamic-pituitary-adrenal" (HPA) axis responds differently to acute psychological stress according to the time of day.
However, according to a study presented at the American College of
Neuropsychopharmacology, even short periods of sleep deprivation in teens could raise their risk for depression and addiction.
New trials will start However, Prof David director of
neuropsychopharmacology at Imperial, said: "initial findings are exciting."
The research was funded by the National Institute on Alcohol Abuse and Alcoholism and was published in
Neuropsychopharmacology.
Presentations at symposia at international meetings also have taken place or are ongoing, including a scientific session at the 2016 American Psychiatric Association (APA) annual meeting and another planned for the Presidential Symposium at 2017 APA annual meeting; other presentations are scheduled at the American College of
Neuropsychopharmacology in December 2017 and the European College of
Neuropsychopharmacology in September 2017.